Identification of serum biomarker panel to differentiate malignant from benign thyroid nodules using multiplex bead assay

Journal of the Egyptian National Cancer Institute

Table 5 Agreement and diagnostic performance of the significant serum markers

	BTNN/P	MTN N/P	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	Accuracy
IL-8 > 11.46	16/4	5/15	75	80	78.9	76.2	77.5
EGF > 30.24	17/3	3/17	85	85	85.0	85.0	85.0
HGF > 106.2	10/10	2/18	90	50	64.3	83.3	70.0
MIG > 623.8	19/1	9/11	55	95	91.7	67.9	75.0
Ang-1 > 45797	12/8	3/17	85	60	68.0	80.0	72.5
IL8 > 11.46 EGF > 30.24	13/7	1/19	95	65	73.08	92.86	80.0
IL8 > 11.46 EGF > 30.24 Ang-1 > 45797	12/8	1/19	95	60	70.37	92.31	77.5
IL8 > 11.46 EGF > 30.24 MIG > 623.8	13/7	1/19	95	65	73.08	92.86	80.0
IL8 > 11.46 EGF > 30.24 HGF > 106.2	9/11	0/20	100	45	64.52	100.0	72.50
IL-8 > 11.46 EGF > 30.24 HGF > 106.2 MIG > 623.8	9/11	0/20	100	45	64.52	100.0	72.50

All serum values are expressed in pg/ml
Ang-1 angiopoietin-1, AUC area under the curve, CI confidence intervals, EGF epidermal growth factor, HGF hepatocyte growth factor, IL-8 interleukin-8, MIG monokine induced by interferon gamma, BTN benign thyroid nodule, MTN malignant thyroid nodule, N/P number of “negative/positive” was assigned to patient who was below/above the cut-offs assigned by the Youden index, NPV negative predictive value, PPV positive predictive value